Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Collplant Holdings ( (CLGN) ) has shared an update.
On March 23, 2026, CollPlant Biotechnologies received a Nasdaq notice that its ordinary shares had closed below $1.00 for 30 consecutive business days, putting the company out of compliance with Nasdaq Listing Rule 5550(a)(2). Under Nasdaq rules, CollPlant has until September 21, 2026 to restore its bid price to at least $1.00 for 10 consecutive business days, during which time its shares will continue trading on the Nasdaq Capital Market.
If CollPlant fails to regain compliance by September 21, 2026, it may qualify for a second 180-day grace period provided it meets other listing standards and commits to curing the deficiency, potentially via a reverse share split. The notification heightens delisting risk and underscores continued share-price pressure, but the extended timeline gives management room to consider remedial actions while maintaining the stock’s current Nasdaq listing in the near term.
The most recent analyst rating on (CLGN) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.
Spark’s Take on CLGN Stock
According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.
The score is held down primarily by weak financial performance—large ongoing losses, heavy cash burn, and a shrinking equity base despite some TTM revenue and gross margin improvement. Technicals provide partial support with a stronger short-term trend, but longer-term trend and momentum are mixed. Valuation remains unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on CLGN stock, click here.
More about Collplant Holdings
CollPlant Biotechnologies Ltd. is an Israel-based regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on proprietary recombinant human collagen (rhCollagen) produced via plant-based genetic engineering, targeting tissue repair, aesthetics and organ manufacturing, and include a dermal and soft tissue filler collaboration with Allergan, an AbbVie company.
Average Trading Volume: 80,540
Technical Sentiment Signal: Sell
Current Market Cap: $8.74M
For an in-depth examination of CLGN stock, go to TipRanks’ Overview page.